News

GP Pharm participates a the “Forum de la Bioregió 2009”
14-12-2009

Nearly 600 attendees from several areas, industrial, investment, researchers, research centers, universities and hospitals participated in the second Bioregion Summit held in Barcelona las December 13th 2009. As it happened in the previous Summit, “El Fórum” exhibited nearly 80 corporative posters from different companies, research centres and other centres related to biotechnological sector, leading the event to become a meeting and a networking point for professionals of such sector. Amongst all of them GP Pharm was invited to participate as one of the companies applying biotechnological solutions within the pharmaceutical industry

Dr Antonio Parente, GP Pharm’s President, participated during this event in the round table “Bio-entrepreneur's Black Book”, where it was analyzed contradictions between necessities for research, development and innovation and certain business strategies within biological technologies and sciences field.

First report on the sector in Catalonia

Presentation of the 2009 Biocat Report generated high expectations. CEO of Biocat, Montserrat Vendrell, presented the report to professionals from the sector. The report gives a complete analysis of the biotechnology, biomedical and medical technology sector in Catalonia and is an essential tool for policy-makers in our country. The report is based on information collected in the Biocat Directory-which surveyed 358 companies and nearly 400 research centers and groups, in addition to hospitals, universities, science parks and facilities, and technology platforms- from nearly 150 questionnaires carried out in 2009, which were then cross referenced and extrapolated using a number of nation-wide sector reports.

In the closing presentation, Josep-Lluís Carod-Rovira stressed the Catalan Government’s efforts to make the biotech sector a new production model. To this end, he pointed out the 6,722 million euros earmarked for funding the Strategic Agreement for the Internationalization, Employment and Competitiveness of the Catalan Economy in 2010 and fiscal benefits for business angels. According to the vice president of the Government, this last measure is “particularly important” for the biotech sector, as it is difficult for many innovative companies to find venture capital. Furthermore, he reminded participants that the Government is not only dedicating resources to the sector, they are also committed to internationalization tasks, “understanding that one of the most important challenges facing Catalan biotech companies is moving into markets in the United States and Asia.”

pgpharm-bioregio-en.pdf